Catalent paves the way for Novos US GLP-1 expansion A substantial increase in semaglutide fill/finish capacity in the US is expected by bringing Catalent sites in-house, says one analyst
Materials and methods An extensive literature search was carried out independently on online databases (MEDLINE via PubMed, ISI Web of Science, and Scopus), by four reviewers (RMR, EM, LC, and CV) independently of each other, to identify relevant studies published between January 2005 and June 2025
Triggering vagal afferents, GLP-1 mediates signaling from gut to brain with anorexigenic effects and via nerve terminals in the hepatoportal region, it can affect metabolic functions in the liver (15)
How IPC Solves the Cold Chain Challenges of Semaglutide Shipping The demand for GLP-1 medications has increased the complexity of pharmaceutical shipping
The heavy consumption of ethanol for greater than 2 weeks has been reported to reduce the absorption of Methylcobalamin, vitamin B12
